Viatris (VTRS) Shares Outstanding (2019 - 2026)
Viatris (VTRS) posted Shares Outstanding (Entity) of $1.1 billion for Q2 2026, down 1.37% on a QoQ basis from $1.2 billion in Q1 2026, and down 1.48% year-over-year from $1.2 billion in Q2 2025.
Analysis
Viatris (VTRS) Shares Outstanding (2019 - 2026) Analysis & Trends
Viatris has reported Shares Outstanding (Entity) for 8 years, with the latest figure at $1.1 billion in Q2 2026.
- On a quarterly basis, Shares Outstanding (Entity) fell 1.48% year-over-year to $1.1 billion in Q2 2026; TTM through Jun 2026 was $1.1 billion, a 1.48% decrease from a year earlier, with the FY2025 full-year figure at $1.2 billion, down 3.54% from the prior year.
- Shares Outstanding (Entity) was $1.1 billion for Q2 2026 at Viatris, down from $1.2 billion in the prior quarter.
- The five-year high for Shares Outstanding (Entity) was $1.2 billion in Q3 2022, with the low at $1.1 billion in Q2 2026.
- Average Shares Outstanding (Entity) over 5 years is $1.2 billion, with a median of $1.2 billion recorded in 2024.
- The sharpest annual moves came in 2024 and 2025: Shares Outstanding (Entity) increased 0.52% in 2024, then dropped 3.54% in 2025.
- Over 5 years, Shares Outstanding (Entity) stood at $1.2 billion in 2022, then dropped by 0.77% to $1.2 billion in 2023, then gained by 0.52% to $1.2 billion in 2024, then slipped by 3.54% to $1.2 billion in 2025, then decreased by 0.24% to $1.1 billion in 2026.
- The last three Shares Outstanding (Entity) figures came in at $1.1 billion (Q2 2026), $1.2 billion (Q1 2026), and $1.2 billion (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.84 Bn | 39.19 Bn | 2.15 Bn | 1.17 Bn |
| 2 | Viatris | 19.13 Bn | 18.24 Bn | 1.46 Bn | 1.16 Bn |
| 3 | Dr Reddys Laboratories | 9.91 Bn | 9.74 Bn | 396.53 Mn | 832.44 Mn |
| 4 | Amneal Pharmaceuticals | 5.51 Bn | 5.38 Bn | 334.51 Mn | 319.20 Mn |
| 5 | Bausch Health Companies | 2.30 Bn | 464.50 Mn | 2.10 Bn | 375.00 Mn |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn | 289.73 Mn |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn | 21.16 Mn |
| 8 | Amphastar Pharmaceuticals | 1.00 Bn | 714.13 Mn | 93.47 Mn | 43.64 Mn |
| 9 | Fennec Pharmaceuticals | 402.10 Mn | 360.85 Mn | 17.15 Mn | 34.55 Mn |
| 10 | RedHill Biopharma | 178.35 Mn | 178.35 Mn | - | 259.12 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.16 Bn |
| Mar 31, 2026 | 1.16 Bn |
| Dec 31, 2025 | 1.16 Bn |
| Sep 30, 2025 | 1.16 Bn |
| Jun 30, 2025 | 1.17 Bn |
| Mar 31, 2025 | 1.19 Bn |
| Dec 31, 2024 | 1.19 Bn |
| Sep 30, 2024 | 1.19 Bn |
| Jun 30, 2024 | 1.19 Bn |
| Mar 31, 2024 | 1.20 Bn |
| Dec 31, 2023 | 1.20 Bn |
| Sep 30, 2023 | 1.20 Bn |
| Jun 30, 2023 | 1.20 Bn |
| Mar 31, 2023 | 1.20 Bn |
| Dec 31, 2022 | 1.21 Bn |
| Sep 30, 2022 | 1.21 Bn |
| Jun 30, 2022 | 1.21 Bn |
| Mar 31, 2022 | 1.21 Bn |
| Dec 31, 2021 | 1.21 Bn |
| Sep 30, 2021 | 1.21 Bn |